Core Viewpoint - Microchip Biotech (688321.SH) forecasts a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the previous year, thus achieving a turnaround from loss to profit [1] Group 1: Financial Performance - The company expects a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, which represents a year-on-year increase of about 168.03 million yuan [1] - The company's revenue is projected to grow significantly, driven by the commercial success of its products [1] Group 2: Product Performance - The product Siglecatinib has shown remarkable commercial effectiveness, with sales revenue increasing by approximately 123% year-on-year due to its unique clinical value in "diabetes liver management" and the expansion of self-operated, strategic partnerships, and new retail channels [1] - The product Sidabenamine has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025, contributing to a year-on-year sales revenue growth of about 16% [1]

Core Viewpoint - Microchip Biotech (688321.SH) is expected to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the same period last year, thus turning a profit [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, representing a year-on-year increase of about 168.03 million yuan, indicating a turnaround from loss to profit [1] - The company's revenue is expected to grow significantly, driven by the sales of its product, Siglecatin Sodium, which has seen a year-on-year increase of around 123% due to its unique clinical value and effective commercialization strategies [1] Group 2: Product Development and Market Recognition - The product, Sidabamine, has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025 [1] - The inclusion of Sidabamine in the latest version of the National Medical Insurance Directory under regular Class B management in December 2025 is expected to contribute to a year-on-year revenue growth of approximately 16% [1]

Group 1 - The company Microchip Biotech expects to achieve a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168 million yuan compared to the same period last year, thus turning a profit [1] - The significant change in performance is attributed to the product Sigleptin's unique clinical value in "diabetes and liver management," along with efforts in self-operated, strategic partnerships, and new retail channels, resulting in a sales revenue increase of approximately 123% year-on-year [1] - The product Sidabenamine has gained support from the National Healthcare Security Administration and market recognition, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Catalog in January 2025, leading to a year-on-year sales revenue growth of about 16% [1]

Core Viewpoint - Microchip Biotech (688321.SH) expects to achieve an annual revenue of approximately 910.08 million yuan in 2025, representing a year-on-year growth of about 38.32% [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 53.46 million yuan in 2025, an increase of about 168.03 million yuan compared to the previous year, marking a turnaround from losses to profits [1] - The expected net profit excluding non-recurring gains and losses is around 38.14 million yuan [1] Product Performance - The product Sigleptin Sodium has shown significant commercial success with a sales revenue increase of approximately 123% year-on-year, driven by its unique clinical value in "diabetes and liver management" and enhanced distribution through self-operated, strategic partners, and new retail channels [1] - The product Sidabenamine has gained recognition for its clinical value, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025, leading to a year-on-year sales revenue growth of about 16% [1]

证券代码：688321 证券简称：微芯生物 公告编号：2026-008 深圳微芯生物科技股份有限公司 2025 年年度业绩预告公告 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）公司预计 2025 年年度实现营业收入 91,008.00 万元左右， 同比增长 38.32%左右。 （三）本次业绩预告的相关财务数据未经注册会计师审计。 （2）公司预计 2025 年年度实现归属于上市公司股东的净利润 5,346.00 万元左右，比上年同期增加 16,803.06 万元左右，将实现 扭亏为盈。 （3）公司预计 2025 年年度实现归属于上市公司股东的扣除非经 常性损益的净利润 3,814.00 万元左右。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 二、上年同期业绩情况和财务状况 特此公告。 深圳微芯生物科技股份有限公司董事会 2026 年 1 月 27 日 四、风险提示 截至本公告出具日，公司未发现可能影响本次业绩预告内容准确 性的重 ...

微芯生物公告，预计2025年年度实现营业收入9.1亿元左右，同比增长38.32%左右；预计实现归属于上 市公司股东的净利润5346万元左右，比上年同期增加1.68亿元左右，将实现扭亏为盈；预计实现归属于 上市公司股东的扣除非经常性损益的净利润3814万元左右。 ...

南财智讯1月26日电，微芯生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 5,346.00万元左右，预计同比扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润 为3,814.00万元左右；本报告期内，公司产品西格列他钠依托"糖肝共管"独特的临床价值，叠加自营、 战略合作商与新零售渠道发力，商业化成效显著，销售收入同比增长123%左右；公司产品西达本胺的 临床价值获得国家医保局的支持与市场的认可，新增适应症弥漫大B细胞淋巴瘤于2025年1月纳入《国 家医保目录》，并于同年12月纳入最新版《国家医保目录》常规乙类管理，在医保连续降价以及2025年 第四季度库存补差的影响下，销售收入同比增长16%左右。综上，公司营业收入相应增长，归属母公司 所有者的净利润实现扭亏为盈。 ...

Core Viewpoint - Shenzhen Chipscreen Biosciences Co., Ltd. has announced that its convertible bond, "Chipscreen Convertible Bond," is expected to meet the redemption conditions based on the stock price performance during a specified period [2][8]. Group 1: Convertible Bond Issuance Overview - The company issued 5 million convertible bonds with a total value of RMB 500 million, each with a face value of RMB 100, approved by the China Securities Regulatory Commission on July 5, 2022 [3]. - The bonds have a maturity period of six years, from July 5, 2022, to July 4, 2028, and began trading on the Shanghai Stock Exchange on July 28, 2022, under the name "Chipscreen Convertible Bond" with the code "118012" [3]. Group 2: Redemption Terms and Expected Trigger Conditions - The redemption terms include a mandatory redemption at 115% of the face value plus the last interest payment within five trading days after maturity [5]. - Conditional redemption can occur if the stock price remains at or above 130% of the conversion price for at least 15 out of 30 trading days or if the remaining unconverted bonds are less than RMB 30 million [6][8]. - As of January 22, 2026, the stock price has been above 130% of the conversion price for 10 trading days, and if this trend continues, the company may decide to redeem the bonds [2][8].

| | | 深圳微芯生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳微芯生物科技股份有限公司（以下简称"公司"）股票交易价格自 2026 年 1 月 9 日至 2026 年 1 月 22 日期间，已有 10 个交易日的收盘价格不低 于"微芯转债"当期转股价格的 130%（即 32.838 元/股），若未来连续 20 个交 易日内，仍有 5 个交易日公司股票的收盘价格不低于当期转股价的 130%（含 130%），将触发《深圳微芯生物科技股份有限公司向不特定对象发行可转换公 司债券募集说明书》中规定的有条件赎回条款。届时，公司有权决定是否按照 债券面值加当期应计利息的价格赎回全部或部分未转股的"微芯转债"。 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 的有关规定，公司将可能触发可转换公司债券有条件赎回条款的相关情况公告 如下。 一、可转债发行上市概况 经中国证券监督管理委员会"证监许可[2022]1234 号"文同意注册，公司于 2022 年 7 月 5 ...

Group 1 - The core point of the article is that Shenzhen MicuRx Pharmaceuticals Co., Ltd. and Chengdu MicuRx Pharmaceuticals Co., Ltd. have initiated a Phase III clinical trial for the drug Xioroni in combination with PD-1 monoclonal antibody, albumin-bound paclitaxel, and gemcitabine for the first-line treatment of metastatic pancreatic ductal adenocarcinoma patients [1][2] - The clinical trial aims to evaluate the safety and tolerability of Xioroni in combination with chemotherapy during the induction phase, and the efficacy of the combination regimen during the randomized controlled phase [1] - The trial has a target enrollment of 558 participants and is currently ongoing, with the clinical trial registration number CTR20260141 and the first public information date set for January 15, 2026 [1][2] Group 2 - The primary endpoints of the trial include the incidence and severity of adverse events during the induction phase and overall survival (OS) during the randomized controlled phase [2] - Secondary endpoints encompass various measures such as objective response rate (ORR), duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), and quality of life (QoL) assessments [2] - The drug Xioroni is a chemical medication indicated for metastatic pancreatic ductal adenocarcinoma, a malignancy characterized by high metastatic potential and poor prognosis [1][2]